Navigation Links
Alcohol and sleep restriction can affect young men's alertness and driving performance
Date:10/1/2007

WESTCHESTER, Ill. Combining low-dose alcohol with moderate sleep restriction can have a significant adverse effect on young mens subjective alertness and performance behind the wheel, according to a study published in the October 1 issue of the journal SLEEP.

The study, authored by Andrew Vakulin, of the Adelaide Institute for Sleep Health at Repatriation General Hospital in Australia, focused on 21 healthy young men, aged 18-30 years, who all had normal sleep patterns and no sleep disorders. The participants completed a 70-minute simulated driving session, which included steering deviation, braking reaction time, and number of collisions, and underwent repeated measures with four experimental conditions: normal sleep without alcohol, sleep restriction alone (four hours) and sleep restriction in combination with two different low BACs (0.025 g/dL and 0.035 g/dL).

According to the results, steering deviation increased significantly when sleep restriction was combined with the higher dose alcohol. This combination also resulted in a greater subjective sleepiness and negative driving performance ratings compared to control or sleep restriction alone.

The ability to keep the car in the middle of the lane is critical to safe driving, and is one of the more sensitive measures of driving impairment, said Vakulin. Although steering deviation was not significantly affected by sleep restriction alone, alcohol at a BAC as low as 0.025 g/dL in combination with sleep restriction was sufficient to significantly impair steering ability. This combination may considerably reduce the threshold for safe driving, as suggested by the steering deviation data and an increase in off-road collisions following sleep restriction and alcohol ingestion in this study.

Those who think they might have a sleep disorder are urged to discuss their problem with their primary care physician, who will issue a referral to a sleep specialist.


'/>"/>

Contact: Jim Arcuri
jarcuri@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Controversial drug shown to act on brain protein to cut alcohol use
2. Alcohols effects on gene expression in the central nervous system
3. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
4. Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
5. Alcohol consumption disrupts breastfeeding hormones
6. Investigating brain shrinkage in alcoholics
7. Russian surrogate alcohols are a killer
8. Looking for the genes that affect a persons level of response to alcohol
9. Mapping alcohol brain damage
10. Alcoholism, smoking and genetics among Plains American Indians
11. Genetic and environmental influences on alcohol consumption among rhesus monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology: